FIP1L1 antibody (AA 23-558)
Quick Overview for FIP1L1 antibody (AA 23-558) (ABIN7872545)
Target
See all FIP1L1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 23-558
-
Purpose
- FIP1L1 Antibody / Pre-mRNA 3'-end-processing factor FIP1
-
Purification
- Antigen affinity purified
-
Immunogen
- Recombinant human protein (amino acids E23-E558) was used as the immunogen for the FIP1L1 antibody.
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal dilution of the FIP1L1 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- After reconstitution, the FIP1L1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- FIP1L1 (FIP1 Like 1 (FIP1L1))
-
Alternative Name
- FIP1L1
-
Background
- Factor interacting with PAPOLA and CPSF1 (i.e, FIP1L1, also termed Pre-mRNA 3'-end-processing factor FIP1) is a protein that in humans is encoded by the FIP1L1 gene (also known as Rhe, FIP1, and hFip1). This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
-
UniProt
- Q6UN15
Target
-